Trials
2 active
13 in total · 2 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- How it’s given
- “150 mg linsitinib is taken twice daily by mouth for 24 weeks”In the company’s words, NCT07753603 on ClinicalTrials.gov
- Tested for
- Graves Orbitopathy (2 trials), Thyroid Eye Disease, TED, Thyroid Eye Disease, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases and 5 more
- Main trialPhase 3
- “The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease (TED).”In the company’s words, NCT07753603 on ClinicalTrials.gov
- Other names
- OSI-906
Other drugs for Graves Orbitopathy
Coming up1
- 30 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Jun 2028 | Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED) | |
| Phase 2/3Recruiting | Jun 2026 | Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) | |
| Phase 3Completed | 11 Jul 2012 | A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma | |
| Phase 2/3Completed | 15 Oct 2024 | A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) | |
| Phase 2Terminated | 4 Nov 2011 | A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC | |
| Phase 2Completed | 1 Mar 2013 | Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene | |
| Phase 2Completed | 1 Jul 2013 | Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy | |
| Phase 2Completed | 14 Oct 2016 | A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial | |
| Phase 1/2Completed | 1 Aug 2014 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | |
| Phase 1Completed | 20 Sep 2010 | Study of Intermittent OSI-906 Dosing | |
| Phase 1Completed | 3 Mar 2012 | A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) | |
| Phase 1Completed | 19 Mar 2012 | Study of Continuous OSI-906 Dosing | |
| Phase 1Completed | 8 Dec 2012 | A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026